I worked for many years at an investment firm where I invested across public and private market opportunities. I underwrote fund managers, as well as individual securities. I left the firm to pursue an MBA from a Top-20 US B School. At school, I won the nation's premier stock pitching competition and was portfolio manager for the school's Consumer sector investments. During that time, I interned at a multi-family office and a hedge fund. I became adept at using Bloomberg and Factset for research. On top of ...

BETHLEHEM, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Resp ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics an ...

BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference: Stephens Annual Investment Conference on Wednesday, November 20, with a Q&A session scheduled for 1 p.m. ET A live webcast and replay of the Q&A session will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. The webcast will be archived on OraSure’s ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value ...

Company Performance - OraSure Technologies reported a quarterly loss of $0.01 per share, better than the Zacks Consensus Estimate of a loss of $0.04, and a significant decline from earnings of $0.27 per share a year ago, indicating a 103.7% decrease year-over-year [1] - The company achieved revenues of $39.92 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 1.97%, but down from $89.19 million in the same quarter last year, reflecting a 55.2% decline [2] - Over the last four quarters, OraSure has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - OraSure shares have declined approximately 47.7% since the beginning of the year, contrasting with the S&P 500's gain of 21.2% [3] - The current Zacks Rank for OraSure is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $38.51 million, while for the current fiscal year, the estimate is $0.05 on revenues of $186.12 million [7] - The outlook for the Medical - Products industry, to which OraSure belongs, is currently in the top 36% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

| --- | |--------------------------| | | | | | Investor Contact: | | Jason Plagman | | VP, Investor Relations | | investorinfo@orasure.com | Communications EXHIBIT 99.1 | --- | |---------------------| | | | | | | | Media Contact: | | Amy Koch | | Director, Corporate | | media@orasure.com | OraSure Reports Q3 '24 Revenue of $39.9 Million Q3 GAAP EPS of $(0.06); Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Managem ...

Q3 GAAP EPS of $(0.06); Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics Exiting Risk Assessment testing business to focus on markets with attractive growth opportunities BETHLEHEM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced its fina ...

OraSure Technologies Inc. (NASDAQ: OSUR ), a health and wellness company based in Pennsylvania, is a classic Benjamin Graham-style net current asset value-based investment (NCAV). While the discount to NCAV is only slight, it is perhaps worth the price due toI am a value investor with a concentrated portfolio, focusing on rare and exceptional buying opportunities. As a keen reader of Value Investing literature, I am well versed in the teachings of 'super investors' such as Warren Buffett, Charlie Munger, Be ...

BETHLEHEM, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2024 financial results and certain business developments for 5 p.m. ET on November 6, 2024. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 1 ...